Amino acid domains involved in constitutive activation of G-protein- coupled receptors

Molecular Neurobiology

Volumn 17, Issue 1-3, 1998, Pages 109-135

  Pauwels, Petrus J ^a   Wurch, Thierry ^a  

^a INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

Constitutive receptor activation; G protein coupled receptor; Inverse agonist; Mutant receptor; Negative efficacy

Indexed keywords

GUANINE NUCLEOTIDE BINDING PROTEIN; RECEPTOR PROTEIN; AMINO ACID; CELL SURFACE RECEPTOR; RECOMBINANT PROTEIN;

CONFORMATIONAL TRANSITION; ISOMERISM; MOLECULAR DYNAMICS; MUTATION; NONHUMAN; PROTEIN CONFORMATION; PROTEIN DOMAIN; RECEPTOR INTRINSIC ACTIVITY; RECEPTOR SENSITIVITY; REVIEW; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMAL; CELL MEMBRANE; CHEMICAL STRUCTURE; CHEMISTRY; GENETIC DISORDER; GENETICS; HUMAN; METABOLISM; PHYSIOLOGY; POINT MUTATION; PROTEIN SECONDARY STRUCTURE;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; AMINO ACIDS; ANIMALS; CELL MEMBRANE; GENETIC DISEASES, INBORN; GTP-BINDING PROTEINS; HUMANS; MODELS, MOLECULAR; POINT MUTATION; PROTEIN STRUCTURE, SECONDARY; RECEPTORS, CELL SURFACE; RECOMBINANT PROTEINS;

EID: 0032239841     PISSN: 08937648     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02802027     Document Type: Review

References (140)

1. S α-subunit levels in neuroblastoma x glioma hybrid NG108-15 cells transfected to express different levels of the human β2 adrenoreceptor. Biochem. J. 300, 709-715.
2. Adie E. J. and Milligan G. (1994b) Regulation of basal adenylate cyclase activity in neuroblastoma x glioma hybrid, NG108-15, cells transfected to express the human β2 adrenoreceptor: evidence for empty receptor stimulation of the adenylate cyclase cascade. Biochem. J. 303, 803-808.
3. i activation. J. Mol. Cell. Cardiol. 29, 765-775.
4. 1B-adrenergic receptor enhances mitogenesis and tumorigenicity. Proc. Natl. Acad. Sci. USA 88, 11,354-11,358.
5. Arden J. R., Nagata O., Shockley M. S., Philip M., Lameh J., and Sadée W. (1992) Mutational analysis of third cytoplasmic loop domains in G-protein coupling of the HM1 muscarinic receptor. Biochem. Biophys. Res. Comm. 188, 1111-1115.
6. Baldwin J., (1993) The probable arrangement of the helices in G protein-coupled receptors. EMBO J. 12, 1693-1703.
7. 2C) receptors reveal novel inverse agonist activity of receptor ligands. J. Biol. Chem. 269, 11,687-11,690.
8. Bastepe M. and Ashby B. (1997) The long cytoplasmic carboxyl terminus of the prostaglandin E2 receptor EP4 subtype is essential for agonist-induced desensitization. Mol. Pharmacol. 51, 343-349.
9. Baxter G. S. and Tilford N. S. (1995) Endogenous ligands and inverse agonism. Trends Pharmacol. Sci. 16, 258-259.
10. Bertaccini G. and Coruzzi G. (1992) in Histamine Receptors in the Digestive System. (Schwartz J-C., and Haas H. L., eds.) Wiley-Liss, New York, pp. 193-231.
11. Bond R. A., Leff P., Johnson T. D, Milano C. A., Rockman H. A., McMinn T. R., Apparsundaram S., Hyek M. F., Kenakin T. P., Allen L. F., and Lefkowitz R. J. (1995) Physiological effects of inverse agonists in transgenic mice with myocardial overexpression of the β2-adrenoreceptor. Nature (London) 374, 272-276.
12. Boone C., Davis N. G., and Sprague G. F. (1993) Mutations that alter the third cytoplasmic loop of the α-factor receptor lead to a constitutive and hypersensitive phenotype. Proc. Natl. Acad. Sci. USA 90, 9921-9925.
13. 2-adrenergic receptor delays onset of agonist-promoted desensitization. Nature (London) 333, 370-373.
14. Braestrup C., Schmiechen R., Neef G., Nielsen M., and Petersen E. N. (1982) Interaction of convulsive ligands with benzodiazepine receptors. Science 216, 1241-1243.
15. Brandl C. J. and Deber C. M. (1986) Hypothesis about the function of membrane-buried proline residues in transport proteins. Proc. Natl. Acad. Sci. USA 83, 917-921.
16. Burstein E. S., Spalding T. A., Hill-Eubanks D., and Brann M. R. (1995) Structure-function of muscarinic receptor coupling to G proteins. Random saturation mutagenesis identifies a critical determinant of receptor affinity for G proteins. J. Biol. Chem. 270, 3141-3146.
17. Burstein E. S., Spalding T. A., and Brann M. R. (1997) Pharmacology of muscarinic receptor subtypes constitutively activated by G proteins. Mol. Pharmacol. 51, 312-319.
18. 2A receptor mutagenesis reveals a receptor which has radioligand binding properties indicative of onstitutive activity. Experimental Biology 96™ Washington, D.C., April 14-17, 1996.
19. 2-adrenergic receptor: Reconstitution of functional interactions between pure receptor and pure stimulatory nucleotide binding protein of the adenylate cyclase system. Biochemistry 23, 4519-4525.
20. Charpentier S., Jarvie K. R., Severynse D. M., Caron M. G., and Tiberi M. (1996) Silencing of the constitutive activity of the dopamine D1B receptor. Reciprocal mutations between D1 receptor subtypes delineate residues underlying activation properties. J. Biol. Chem. 271, 28,071-28,076.
21. Chidiac P., Hebert T. E., Valiquette M., Dennis M., and Bouvier M. (1994) Inverse agonist activity of β-adrenergic antagonists. Mol. Pharmacol. 45, 490-499.
22. Chiu T. T., Yung L. Y., and Wong Y. H. (1996) Inverse agonistic effect of ICI-174,864 on the cloned δ-opioid receptor: role of G protein and adenylyl cyclase activation. Mol. Pharmacol. 50, 1651-1657.
23. 1 dopamine receptor binding and signal transduction. Mol. Pharmacol. 50, 1338-1345.
24. Cohen G. B., Yang T., Robinson P. R., and Oprian D. D. (1993) Constitutive activation of opsin: influence of charge at position 134 and size at position 296. Biochemistry 32, 6111-6115.
25. Costa T. and Herz A. (1989) Antagonists with negative intrinsic activity at delta opioid receptors coupled to GTP-binding proteins. Proc. Natl. Acad. Sci. USA 86, 7321-7325.
26. Costa T., Lang J., Gless C., and Herz A. (1990) Spontaneous association between opioid receptors and GTP-binding regulatory proteins in native membranes: specific regulation by antagonist and sodium ions. Mol. Pharmacol. 37, 383-394.
27. Costa T., Ogino Y., Munson P. J., Onaran H. O., and Rodbard D. (1992) Drug efficacy at guanine nucleotide-binding regulatory protein-linked receptors: thermodynamic interpretation of negative antagonism and of receptor activity in the absence of ligand. Mol. Pharmacol. 41, 549-560.
28. 1-adrenergic receptor involved in coupling to phosphatidylinositol hydrolysis and enhanced sensitivity of biological function. Proc Natl. Acad. Sci. USA 87, 2896-2990.
29. Coughlin S. R. (1994) Expanding horizons for receptors coupled to G proteins: diversity and disease. Curr. Opin. Cell. Biol. 6, 191-197.
30. 2A-adrenergic receptor alter receptor G-protein coupling by distinct mechanisms. J. Biol. Chem. 266, 11,025-11,029.
31. 2-receptor antagonists in peptic ulcer disease. Efficacy in healding peptic ulcers. Drugs 44, 709-719.
32. De Lean A., Stadel J. M., and Lefkowitz R. J. (1980) A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled beta-adrenergic receptor. J. Biol. Chem. 255, 7108-7117.
33. Dixon R. A. F., Signal I. S., and Strader C. D. (1988) Structure-function analysis of the β-adrenergic receptor. Cold Spring Harbor Symp. Quant. Biol. 53, 487-497.
34. Dryja T. P., Mcgee T. L., Reichel E., Hahn L. B., Cowley G. S., Yandell D. W., Olsson J. E., Sandberg M. A., and Berson E. L. (1990a) A point mutation of the rhodopsin gene in one form of retinitis pigmentosa. Nature 343, 364-366.
35. Dryja T. P., Mcgee T. L., Hahn L. B., Cowley G. S., Olsson J. E., Reichel E., Sandberg M. A., and Berson E. L. (1990b) Mutations within the rhodopsin gene in patients with autosomal dominant retinitis pigmentosa. N. Engl. J. Med. 232, 1302-1307.
36. Dryja T. P., Berson E. L., Rao V. H., and Oprian D. D. (1993) Heterozygous missense mutation in the rhodopsin gene as a cause of congenital stationary night blindness. Nature Genet. 4, 280-283.
37. Götze K. and Jakobs K. H. (1994) Unoccupied β-adrenoceptor-induced adenylyl cyclase stimulation in turkey erythrocyte membranes. Eur. J. Pharmacol. 268, 151-158.
38. 1A angiotensin II receptor induces its constitutive activation. J. Biol. Chem. 272, 1822-1826.
39. 3 receptor. J. Neural Transm. 103, 1163-1175.
40. 2 dopamine receptors. Br. J. Pharmacol. 121, 731-736.
41. + currents in frog and rat cardiac cells. J. Physiol. (London) 461, 743-765.
42. 2C receptor antagonists. J. Biol. Chem. 271, 22591-22597.
43. Hausdorff W. P., Bouvier M., O'Dowd B. F., Irons G. P., Caron M. G., and Lefkowitz R. J. (1989) Phosphorylation sites on two domains of the beta 2-adrenergic receptor are involved in distinct pathways of receptor desensitization. J. Biol. Chem. 264, 12,657-12,665.
44. Hausdorff W. P., Caron M. G., and Lefkowitz R. J. (1990) Turning off the signal: desensitization of β-adrenergic receptor function. FASEB J. 4, 2881-2889.
45. Heinflink M., Nussenzveig D. R., Grimberg H., Lupu-Meiri M., Oron Y., and Gershengorn M. C. (1995) A constitutively active mutant thyrotropin-releasing hormone receptor is chronically down-regulated in pituitary cells: evidence using chlordiazepoxide as a negative antagonist. Mol. Endocrinol. 9, 1455-1460.
46. Hibert M. F., Trumpp-Kallmeyer S., Bruinvels A., and Hoflack J. (1991) Three-dimensional models of neurotransmitter G-binding protein-coupled receptors. Mol. Pharmacol. 40, 8-15.
47. Hilf G. and Jakobs, K. H. (1992) Agonist-independent inhibition of G protein activation by muscarinic acetylcholine receptor antagonists in cardiac membranes. Eur. J. Pharmacol. Mol. Pharmacol. Section 225, 245-252.
48. Högger P., Shockley M. S., Lameh J., and Sadée W. (1995) Activating and inactivating mutations in N-and C-terminal i3 loop junctions of muscarinic acetylcholine Hm1 receptors. J. Biol. Chem. 270, 7405-7410.
49. Hwa J., Graham R. M., and Perez D. M. (1996) Chimeras of α1-adrenergic receptor subtypes identify critical residues that modulate active state isomerization. J. Biol. Chem. 271, 7956-7964.
50. 1-adrenergic receptor activation. Biochemistry 36, 633-639.
51. Ishii I., Izumi T., Tsukamoto H., Umeyama H., Ui M., and Shimizu T. (1997) Alanine exchanges of polar amino acids in the transmembrane domains of a platelet-activating factor receptor generate both constitutively active and inactive mutants. J. Biol. Chem. 272, 1846-1854.
52. 3 isoforms. Br. J. Pharmacol. 121, 317-323.
53. Jones P. G., Curtis C. A. M., and Hulme E. C. (1995) The function of a highly-conserved arginine residue in activation of the muscarinic ml receptor. Eur. J. Pharmacol. 288, 251-257.
54. Keen T. J., Inglehearn C. R, Lester D. H., Bashir R., Jay M., Bird A. C., Jay B., and Bhattacharya S. S. (1991) Autosomal dominant retinitis pigmentosa: four new mutations in rhodopsin, one of them in the retinal attachment site. Genomics 11, 199-205.
55. Kenakin T. (1995) Pharmacological Proteus? Trends Pharmacol. Sci. 16, 256-258.
56. Kim G. D., Carr I. C., and Milligan G. (1995) Detection and analysis of agonist-induced formation of the complex of the stimulatory guanine nucleotide-binding protein with adenylate cyclase in intact wild-type and beta 2-adrenoreceptor-expressing NG108-15 cells. Biochem. J. 308, 275-281.
57. 1B-adrenergic receptor by all amino acid substitutions at a single site: evidence for a region which constrains receptor activation. J. Biol. Chem. 267, 1430-1433.
58. 2-adrenergic receptors: delineation of domains involved in effector coupling and ligand binding specifity. Science 240, 1310-1316.
59. Konopka J. B., Jenness D. D., and Hartwell L. H. (1988) The C-terminus of the S. cerevisiae α-pheromone receptor mediates and adaptative response to pheromone. Cell 54, 609-620.
60. Konopka J. B., Margarit S. M., and Dube P. (1996) Mutation of Pro-258 in transmembrane domain 6 constitutively activates the G protein-coupled α-factor receptor. Proc. Natl. Acad. Sci. USA 93, 6764-6769.
61. Kopp P., Van Sande J., Parma J., Duprez L., Gerber H., Joss E., Jameson J. L., Dumont J. E., and Vassart G. (1995) Brief report: congenital hyperthyroidism caused by a mutation in the thyrotropin-receptor gene. N. Engl. J. Med. 332, 150-154.
62. Kosugi S., Van Dop C., Geffner M. E., Rabl W., Carel J-C., Chaussain J-L., Mori T., Merendino J. J. Jr., and Shenker A. (1995) Characterization of heterogenous mutations causing constitutive activation of the luteinizing hormone receptor in familial male precocious puberty. Human Mol. Genet. 4, 183-188.
63. Kremer H., Mariman E., Otten B. J., Moll G. W., Stoelinga G. B. A., Wit J. M., Jansen M., Drop S. L., Faas B., Ropers H-H., and Brunner H. G. (1993) Cosegregation of missense mutations of the luteinizing hormone receptor gene with familial male-limited precocious puberty. Human Mol. Genet. 2, 1779-1783.
64. Kudo M., Osuga Y., Kobilka B. K., and Hsueh A. J. W. (1996) Transmembrane regions V and VI of the human luteinizing hormone receptor are required for constitutive activation by a mutation in the third intracellular loop. J. Biol. Chem. 271, 22,470-22,478.
65. Labrecque J., Fargin A., Bouvier M., Chidiac P., and Dennis M. (1995) Serotoninergic antagonists differentially inhibit spontaneous activity and decrease ligand binding capacity of the rat 5-hydroxytryptamine type 2C receptor in Sf9 cells. Mol. Pharmacol. 48, 150-159.
66. Latronico A. C., Anasti J., Arnhold I. J. P., Mendonca B. B., Domenice S., Albano M. C., Zachman K., Wajchenberg B. L., and Tsigos C. (1995) A novel mutation of the luteinizing hormone receptor gene causing male gonadotropin-independent precocious puberty. J. Clin. Endocrinol. Metab. 80, 2490-2494.
67. Laue L., Chan W-Y., Hsueh A. J. W., Kudo M., Hsu S. Y., Wu S-M., Blomberg L., and Cutler G. B. Jr. (1995) Genetic heterogeneity of constitutively activating mutations of the human luteinizing hormone receptor in familial male-limited precocious puberty. Proc. Natl. Acad. Sci. USA 92, 1906-1910.
68. Laue L., Wu S-M., Kudo M., Hsueh A. J. W., Cutler G. B. Jr., Jelly D. H., Diamond F. B., and Chan W-Y. (1996) Heterogeneity of activating mutations of the human luteinizing receptor in male-limited precocious puberty. Biochem. Mol. Medicine. 7, 192-198.
69. Leeb-Lundberg F. L. M., Mathis S. A., and Herzig M. C. S. (1994) Antagonists of bradykinin that stabilize a G-protein-uncoupled state of the B2 receptor act as inverse agonists in rat myometrial cells. J. Biol. Chem. 269, 25,970-25,973.
70. Leff P. (1995) The two-state model of receptor activation. Trends Pharmacol. Sci. 16, 89-97.
71. Lefkowitz R. J., Cotecchia S., Samama P., and Costa T. (1993) Constitutive activity of receptors coupled to guanine nucleotide regulatory proteins. Trends Pharmacol. Sci. 14, 303-307.
72. Lundell L., Backman L., Eström P., Enander L. K., Falkmer S., Fausa O., Grimelius L., Havu N., Lind T., Lonroth H., Sandmark S., Sandzen B., Unge P., and Westin I. H. (1991) Scand. J. Gastroenterol. 26, 248-256.
73. Ma H. and Green R. D. (1992) Modulation of cardiac cyclic AMP metabolism by adenosine receptor agonists and antagonists. Mol. Pharmacol. 12, 831-837.
74. 2-adrenoreceptor in transfected neuroblastoma X glioma hybrid cells. Mol. Pharmacol. 50, 1479-1486.
75. Merki H. S. and Wilder-Smith C. H. (1994) Do continuous infusions of omeprazole and ranitidine retain their effect with prolonged dosing? Gastroenterology 106, 60-64.
76. Mewes T., Dutz S., Ravens U., and Jakobs K. H. (1993) Activation of calcium currents in cardiac myocytes by empty β-adrenoceptors. Circulation 88, 2916-2922.
77. 2-adrenergic receptor. Science 264, 582-586.
78. 1B-adrenergic receptor in transgenic mice induces cardiac hypertrophy. Proc. Natl. Acad. Sci. USA 91, 10109-10113.
79. Milligan G., Bond R. A., and Lee M. (1995) Inverse agonism: pharmacological curiosity or potential therapeutic strategy? Trends Pharmacol. Sci. 16, 10-13.
80. Murray R. and Keenan A. K. (1989) The β-adrenoceptor is precoupled to Gs in chicken erythrocyte membranes. Cell. Signal. 1, 173-179.
81. Nanevicz T., Wang L., Chen M., Ishii M., and Coughlin S. R. (1996) Thrombin receptor activating mutations. Alteration of an extracellular agonist recognition domain causes constitutive signaling. J. Biol. Chem. 271, 702-706.
82. Nerme V., Severne Y., Abrahamsson T., and Vauquelin G. (1986) Spontaneous coupling of the β-adrenergic receptor to Ns in mammalian cardiac membranes. Mol. Pharmacol. 30, 1-5.
83. 2 adrenergic receptors: evidence for a precoupled receptor-guanine nucleotide protein complex. Biochemistry 27, 2374-2384.
84. 1A receptors by the inverse agonist, spiperone but not the neutral antagonist, WAY 100,635. Br. J. Pharmacol. 120, 737-739.
85. Nwokolo C. U., Mistry P., and Pounder R. E. (1990) The absorption of bismuth and salicylate from oral doses of Pepto-Bismol (bismuth salicylate). Aliment. Pharmacol. Ther. 4, 163-169.
86. 2-adrenergic receptor. Localization of regions involved in G protein-receptor coupling. J. Biol. Chem. 263, 15985-15992.
87. 2-adrenergic receptor that is autoregulated via protein kinase A-dependent phosphorylation. Cell 67, 723-730.
88. 2-adrenergic receptors based upon characteristics in primary structure. J. Biol. Chem. 267, 8342-8346.
89. Parent J-L., Le Gouill C., de Brum-Fernandes A. J., Rola-Pleszczynski M., and Stankova J. (1996) Mutations of two adjacent amino acids generate inactive and constitutively active forms of the human platelet-activating factor receptor. J. Biol. Chem. 271, 7949-7955.
90. Parma J., Duprez L., Van Sande J., Cochaux P., Gervy C., Mockel J., Dumont J., and Vassart G. (1993) Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas. Nature 365, 649-651.
91. Parma J., Duprez L. Van Sande J., Paschke R., Tonacchera M., Dumont J., and Vassart G. (1994) Constitutively active receptors as a disease-causing mechanism. Mol. Cell. Endocrinol. 100, 159-162.
92. Paschke R., Tonacchera M., Van Sande J., Parma J., and Vassart G. (1994) Identification and functional characterization of two new somatic mutations causing constitutive activation of the thyrotropin receptor in hyperfunctioning autonomous adenomas of the thyroid. J. Clin. Endocrinol. Metab. 79, 1785-1789.
93. 1B/D receptor antagonists. Gen. Pharmacol. 29, 293-303.
94. 1B/D receptor ligands: an answer from GTPγS binding studies with stably transfected C6-glial cell lines. Neuropharmacology 36, 499-512.
95. 1A receptor antagonists in recombinant cell lines: modulation of apparent efficacy by G-protein activation state. Naunyn-Schmiedeberg's Arch. Pharmacol. 356, 551-561.
96. 2-adrenergic receptor is constitutively desensitized and phosphorylated. Proc. Natl. Acad. Sci. USA 91, 2699-2702.
97. Perez D. M., Hwa J., Gaivin R., Mathur M., Brown F., and Graham R. M. (1996) Constitutive activation of a single effector pathway: evidence for multiple activation states of a G protein-coupled receptor. Mol. Pharmacol. 49, 112-122.
98. Porcellini A., Ciullo I., Laviola L., Amabile G., Fenzi G., and Avvedimento V. E. (1994) Novel mutations of thyrotropin receptor gene in thyroid hyperfunctioning adenomas. J. Clin. Endocrinol. Metab. 79, 657-661.
99. Pozvek G., Hilton J. M., Quiza M., Houssami S., and Sexton P. M. (1997) Structure/function relationships of calcitonin analogues as agonists, antagonists, or inverse agonists, in a constitutively activated receptor cell system. Mol. Pharmacol. 51, 658-665.
100. Probst W. C., Snyder L. A., Schuster D. I., Brosius J., and Sealfon S. C. (1992) Sequence aligment of the G protein coupled receptor superfamily. DNA Cell. Biol. 11, 1-20.
101. Rao V. R., Cohen G. B., and Oprian D. D. (1994) Rhodopsin mutation G90D and a molecular mechanism for congenital night blindness. Nature 367, 639-642.
102. 2-adrenergic receptor. J. Biol. Chem. 268, 16483-16487.
103. Reneke J. E., Blumer K. J., Courchesne W. E., and Thorner J. (1988) The carboxy-terminal segment of the yeast a-factor receptor is a regulatory domain. Cell 55, 221-234.
104. Rim J. and Oprian D. (1995) Constitutive activation of opsin: interaction of mutants with rhodopsin kinase and arrestin. Biochemistry 34, 11938-11945.
105. Robinson P. R., Cohen G. B., Zhukovsky E. A., and Oprian D. D. (1992) Constitutively active mutants of rhodopsin. Neuron 9, 719-725.
106. Robbins L. S., Nadeau J. H., Johnson K. R., Kelly M. A., Roselli-Rehfuss L. R., Baack E., Mountjoy K. G., and Cone R. D. (1993) Pigmentation phenotypes of variant extension locus alleles result from point mutations that alter MSH receptor function. Cell 72, 827-834.
107. 2-adrenergic receptor: extending the ternary complex model. J. Biol. Chem. 268, 4625-4636.
108. 2-adrenergic receptor. Mol. Pharmacol. 45, 390-394.
109. Samama P., Bond R. A., Rockman H. A., Milano C. A., and Lefkowitz R. J. (1997) Ligand-induced overexpression of a constitutively active β2-adrenergic receptor: pharmacological creation of a phenotype in transgenic mice. Proc. Natl. Acad. Sci. USA 94, 137-141.
110. 1B-adrenergic receptor: role of highly conserved polar amino acids in receptor activation. EMBO J. 15, 3566-3578.
111. 1B-adrenergic receptor: potential role of protonation and hydrophobicity of a highly conserved aspartate. Proc. Natl. Acad. Sci. USA 94, 808-813.
112. Schipani E., Kruse K., and Jüppner H. (1995) A constitutively active mutant PTH-PTHrP receptor in Jansen-type metaphyseal chondrodysplasia. Science 268, 98-100.
113. Schütz W. and Freissmuth M. (1992) Reverse intrinsic activity of antagonists on G protein-coupled receptors. Trends Pharmacol. Sci. 13, 376-380.
114. 2A receptor. J. Biol Chem. 270, 16,683-16,688.
115. Shapiro R. A., Palmer D., and Cislo T. (1993) A deletion mutation in the third cytoplasmic loop of the mouse ml muscarinic acetylcholine receptor unmasks cryptic G-protein binding sites. J. Biol. Chem. 15, 21,734-21,738.
116. Shenker A., Laue L. Kosugi S., Merendino J. J., Minegishi T., and Cutler G. B. (1993) A constitutively activating mutation of the luteinizing hormone receptor in familial male precocious puberty. Nature. 365, 652-654.
117. Shi A-G. and Deth R. C. (1994) Precoupling of alpha-2B adrenergic receptors and G-proteins in transfected PC-12 cell membranes: influence of pertussis toxin and a lysine directed cross-linker. JPET 271, 1520-1527.
118. Smit M. J., Leurs R., Alewijnse A. E., Blauw J., Van Nieuw Amerongen G. P., Van De Vrede Y., Roovers E., and Timmerman H. (1996a) Inverse agonism of histamine H2 antagonists accounts for upregulation of spontaneously active histamine H2 receptors. Proc. Natl. Acad. Sci. USA 93, 6802-6807.
119. 2 receptor contains positive and negative signals important for signal transduction and receptor down-regulation. J. Neurochem. 67, 1791-1800.
120. Spalding T. A., Burnstein E. S., Brauner-Osborne H., Hill-Eubanks D., and Brann M. R. (1995) Pharmacology of a constitutively active muscarinic receptor generated by random mutagenesis. J. Pharmacol. Exp. Ther. 275, 1274-1279.
121. Spalding T. A., Burstein E. S., Wells J. W., and Brann M. R. (1997) Constitutive activation of the m5 muscarinic receptor by a series of mutations at the extracellular end of transmembrane 6. Biochemistry 36, 10109-10116.
122. Spiegel A. M., Shenker A., and Weinstein L. S. (1992) Receptor effector coupling by G proteins: implications for normal and abnormal signal transduction. Endocr. Rev. 13, 536-565.
123. 35S]GTPγS binding. Eur. J. Pharmacol. 320, 267-275.
124. S and increase agonist affinity. J. Biol. Chem. 262, 16,439-16,443.
125. Strader C. D., Candelore M. R., Hill W. S., Sigal I. S., and Dixon R. A. F. (1989) Identification of two serine residues involved in agonist activation of the β-adrenergic receptor. J. Biol. Chem. 264, 13,572-13,578.
126. Sung C. H., Davenport C. M., Hennessey J. C., Maumenee I. H., Jacobson S. G., Heckenlively J. R., Nowakowski R., Fishman G., Gouras P., and Nathans J. (1991a) Rhodopsin mutations in autosomal dominant retinitis pigmentosa. Proc. Natl. Acad. Sci. USA 88, 6481-6485.
127. Sung C. H., Schneider B. G., Agarwal N., Papermaster D. S., and Nathans J. (1991b) Functional heterogeneity of mutant rhodopsins responsible for autosomal dominant retinitis pigmentosa. Proc. Natl. Acad. Sci. USA 88, 8840-8844.
128. 1D receptor subtypes. J. Receptor Res. 15, 199-211.
129. 2-adrenergic receptor activation of G proteins: evidence for a precoupled receptor/G protein state. Mol. Pharmacol. 45, 524-531.
130. Tiberi M. and Caron M. G. (1994) High agonist-independent activity is a distinguishing feature of the dopamine D1B receptor subtype. J. Biol. Chem. 269, 27,925-27,931.
131. Van Sande J., Parma J., Tonacchera M., Swillens S., Dumont J., and Vassart G. (1995) Genetic basis of endocrine disease. Somatic and germline mutations of the TSH receptor gene in thyroid diseases. J. Clin. Endocrinol. Metab. 80, 2577-2585.
132. Von Heijne G. (1991) Proline kinks in transmembrane alpha-helices. J. Mol. Biol. 218, 499-503.
133. Westphal R. S. and Sanders-Bush E. (1994) Reciprocal binding properties of 5-hydroxytryptamine type 2C receptor agonists and inverse agonists. Mol. Pharmacol. 46, 937-942.
134. Westphal R. S., Backstrom J. R., and Sanders-Bush E. (1995) Increased basal phosphorylation of the constitutively active serotonin 2C receptor accompanies agonist-mediated desensitization. Mol. Pharmacol. 48, 200-205.
135. Westphal R. S. and Sanders-Bush E. (1996) Differences in agonist-independent and-dependent 5-Hydroxytryptamine2C receptor-mediated cell division. Mol. Pharmacol. 49, 474-480.
136. 2-receptor antagonists. Dig. Dis. Sci. 35, 976-983.
137. Winderickx J., Lindsey D. T., Sanochi E., Teller D. Y., Motulsky A. G., and Deeb S. S. (1992) Polymorphism in red photopigment underlies variation in colour matching. Nature 356, 431-433.
138. Wong S. E., Parker E. M., and Ross E. (1990) Chimeric muscarinic cholinergic/β-adrenergic receptors that activate Gs in response to mus-carinic agonists. J. Biol. Chem. 265, 6219-6224.
139. Yano K., Hidaka A., Saji M., Polymeropoulos M. H., Okuno A., Kohn L. D., and Cutler G. B. Jr. (1994) A sporadic case of male-limited precocious puberty has the same constitutively activating point mutation in luteinizing hormone/choriogonadotropin receptor gene as familial cases. J. Clin. Endocrinol. Metab. 79, 1818-1823.
140. Yano K., Saji M., Hidaka A., Moriya N., Okuno A., Kohn L. D., and Cutler G. B. Jr. (1995) A new constitutively activating point mutation in the luteinizing hormone/choriogonadotropin receptor gene in cases of male-limited precocious puberty. J. Clin. Endocrinol. Metab. 80, 1162-1168.